Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2026-02-27 @ 3:31 PM
Study NCT ID:
NCT02148718
Status:
COMPLETED
Last Update Posted:
2018-03-01
First Post:
2014-05-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
Sponsor:
AbbVie
Organization:
Study Overview
Official Title:
Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RAPIDA
Brief Summary:
The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2013-004781-34 | EUDRACT_NUMBER | None | View |